BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 1833592)

  • 1. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass.
    Dietrich W; Spannagl M; Schramm W; Vogt W; Barankay A; Richter JA
    J Thorac Cardiovasc Surg; 1991 Oct; 102(4):505-14. PubMed ID: 1833592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
    Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
    ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    de Smet AA; Joen MC; van Oeveren W; Roozendaal KJ; Harder MP; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations.
    Dietrich W; Mössinger H; Spannagl M; Jochum M; Wendt P; Barankay A; Meisner H; Richter JA
    J Thorac Cardiovasc Surg; 1993 Apr; 105(4):712-20. PubMed ID: 7682267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery.
    Bar-Yosef S; Cozart HB; Phillips-Bute B; Mathew JP; Grocott HP
    Can J Anaesth; 2007 Feb; 54(2):107-13. PubMed ID: 17272249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diminished anticoagulant response to heparin in patients undergoing coronary artery bypass grafting.
    Cloyd GM; D'Ambra MN; Akins CW
    J Thorac Cardiovasc Surg; 1987 Oct; 94(4):535-8. PubMed ID: 3498862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of ten percent pentastarch as a cardiopulmonary bypass priming solution. A randomized clinical trial.
    London MJ; Franks M; Verrier ED; Merrick SH; Levin J; Mangano DT
    J Thorac Cardiovasc Surg; 1992 Aug; 104(2):284-96. PubMed ID: 1379660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations.
    Fish KJ; Sarnquist FH; van Steennis C; Mitchell RS; Hilberman M; Jamieson SW; Linet OI; Miller DC
    J Thorac Cardiovasc Surg; 1986 Mar; 91(3):436-42. PubMed ID: 3512919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin resistance after intraoperative platelet-rich plasma harvesting.
    Wickey GS; Keifer JC; Larach DR; Diaz MR; Williams DR
    J Thorac Cardiovasc Surg; 1992 Jun; 103(6):1172-6. PubMed ID: 1597982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost.
    Palatianos GM; Foroulis CN; Vassili MI; Matsouka P; Astras GM; Kantidakis GH; Iliopoulou E; Melissari EN
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):548-54. PubMed ID: 14762367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of antithrombin iii concentrations during cardiopulmonary surgery].
    Sonzogni V; Bellavita P; Carrara B; Cossolini M; Ferri F; Fabretti F; Mamprin F; Pelliccioli I
    Minerva Anestesiol; 2000; 66(1-2):17-23. PubMed ID: 10736978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass.
    Muedra V; Bonanad S; Gómez M; Villalonga V; Sánchez F; Llopis JE
    Perfusion; 2011 Nov; 26(6):487-95. PubMed ID: 21665912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Bajaj T; Fazlollah T; Szlam F; Wilson E; Kaiser A; Tosone SR; Miller BE
    Anesth Analg; 2008 Feb; 106(2):419-25, table of contents. PubMed ID: 18227295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction and elimination of systemic heparinization during cardiopulmonary bypass.
    von Segesser LK; Weiss BM; Garcia E; von Felten A; Turina MI
    J Thorac Cardiovasc Surg; 1992 Apr; 103(4):790-8; discussion 798-9. PubMed ID: 1548923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A clinical study on hemostatic fluctuation during and after cardiopulmonary bypass using hemostatic molecular markers].
    Nakajima H
    Nihon Kyobu Geka Gakkai Zasshi; 1992 Nov; 40(11):1987-97. PubMed ID: 1336789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.